Affiliation:
1. Health Sciences University, Ankara Training and Research Hospital, Ankara, Turkey
Abstract
Introduction: Alopecia areata is a type of non-scarring alopecia, which is thought to be associated with T-cell mediated immune response. Objective: This study aims to compare the levels of serum inflammatory markers before and after treatment in patients with alopecia areata. The study will explore the utility of the systemic immune-inflammation index (SII) in assessing the severity and treatment response in alopecia areata patients. Methods: The study included 60 alopecia areata patients and 40 control patients diagnosed with tinea unguium, aged between 18 and 65 years. Sociodemographic characteristics such as age, gender, and medical history were recorded for both groups. For alopecia areata patients, serum inflammatory markers were recorded before and at the third month of treatment. Serum inflammatory markers for the control group were also recorded. Furthermore, the Severity of Alopecia Tool (SALT) score was calculated for alopecia areata patients before and at the third month of treatment. Results: The alopecia areata group had a significantly higher neutrophil-lymphocyte ratio, mean platelet volume, and SII values compared to the control group, while high-density lipoprotein (HDL) values were significantly lower. Serum inflammatory markers, assessed at the third month of treatment in the alopecia areata group, were lower and HDL values were significantly higher compared to pre-treatment levels. A statistically significant correlation was observed between disease severity and the SII. Conclusion: The SII is a cost-effective marker that can be utilized in assessing the severity of alopecia areata and treatment response.
Reference24 articles.
1. Strazzulla LC, Wang EHC, Avila L, et al. Alopecia areata: Disease characteristics, clinical evaluation, and new perspectives on pathogenesis. J Am Acad Dermatol 2018;78(1):1-12. doi:10.1016/j.jaad.2017.04.1141
2. Zhou C, Li X, Wang C, Zhang J. Alopecia Areata: an Update on Etiopathogenesis, Diagnosis, and Management. Clin Rev Allergy Immunol 2021;61(3):403-423. doi:10.1007/s12016-021-08883-0
3. Dincer Rota D, Tanacan E. The utility of systemic-immune inflammation index for predicting the disease activation in patients with psoriasis. Int J Clin Pract 2021;75(6):e14101. doi:10.1111/ijcp.14101
4. Tanacan E, Dincer D, Erdogan FG, Gurler A. A cutoff value for the Systemic Immune-Inflammation Index in determining activity of Behçet disease. Clin Exp Dermatol2021;46(2):286-291. doi:10.1111/ced.14432
5. Turan Ç, Metin N. A Novel Inflammatory Marker in the Follow-up of Moderate-to-Severe Acne Vulgaris Administered Isotretinoin: Systemic Immune-Inflammation Index (SII). Curr Health Sci J 2022;48(1):63-67. doi:10.12865/CHSJ.48.01.09